Overview

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Purpose of this study was to assess the safety profile and the anti-lymphoma activity of the FC+R combination.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano Studio Linfomi
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine